BiotechTube
Mytos

Mytos

London, United Kingdom· Est.
mytos.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.7M

Overview

Mytos is an automated CDMO for regenerative medicine, leveraging its iDEM™ automation platform to reduce the cost and labor of cell therapy manufacturing. The company targets the critical bottleneck of scalable production for clinical-stage biotechs, offering a 'one-stop-shop' from process development to regulatory support. Backed by over $24M in funding and strategic partnerships with organizations like the CGT Catapult, Mytos aims to make curative cell therapies commercially viable and widely accessible.

Parkinson's DiseaseSensorineural Hearing LossCorneal BlindnessBone Fractures

Technology Platform

iDEM™ (Intelligent Digital Engine for Manufacturing) - A closed, automated platform for scalable 2D adherent cell culture that uses standard T-flasks, enabling direct porting of manual protocols without altering biology. It employs a fleet-based architecture for reliability and claims 10x reductions in labor and cleanroom footprint.

Funding History

1
Total raised:$3.7M
Seed$3.7M

Opportunities

The massive and growing cell therapy market is fundamentally constrained by manual, costly manufacturing.
Mytos's automated CDMO model addresses this core bottleneck, offering a capital-efficient scaling path for dozens of clinical-stage biotechs.
Expansion into a global network of automated sites could position the company as a dominant manufacturing partner for the next generation of regenerative medicines.

Risk Factors

Key risks include the technical challenge of reliably automating complex biological processes at commercial GMP scale for multiple clients.
The company also faces competition from large CDMOs and other automation startups, and its success is inherently tied to the clinical and regulatory success of its clients' therapies, which are often at early stages.

Competitive Landscape

Mytos competes with large, traditional CDMOs (e.g., Lonza, Catalent) that are slowly adopting automation, and with other tech-focused startups (e.g., Culture Biosciences, Ori Biotech) developing cloud-connected or automated bioreactor platforms. Its differentiation lies in its specific focus on 2D adherent cell culture, its fleet-based hardware architecture, and its full-service CDMO wrapper around the technology.

More companies in United Kingdom →